| Name | Title | Contact Details |
|---|
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
Janssen, a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years. We are guided by Our Credo, where our first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use our products and services. Our ultimate goal is to help people live healthy lives.
HCS designs and delivers technology driven therapy management to improve patient initiation, adherence, and persistence. Since 2008, HCS has worked with biopharma brand teams who want to deliver personalized, omni-channel programming with measured outcomes.
NovaDel Pharma is a Flemington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eton is an innovative pharmaceutical company that searches the world over for meaningful therapies that we can bring to patients living with rare diseases.